Prealbumin-to-Globulin Ratio Can Predict the Chemotherapy Outcomes and Prognosis of Patients with Gastric Cancer Receiving First-Line Chemotherapy

Table 1

Baseline characteristics of the patients.

Characteristics	Cases ()	Percentage
Sex
Male	187	66.55%
Female	94	33.45%
Age (yr)
≤60	159	56.58%
>60	122	43.42%
Body mass index (kg/m^2)
<18.5 or >25	72	25.62%
18.5–25	209	74.38%
ECOG
0–1	233	82.92%
≥2	48	17.08%
Histological type
Papillary, tubular,	73	25.98%
Poorly cohesive, mucinous	208	74.02%
TNM stage
III	55	19.57%
IV	226	80.43%
Number of organs affected by metastasis
0–1	190	67.62%
≥2	91	32.38%
Peritoneal metastasis
Yes	91	32.38%
No	190	67.62%
First-line chemotherapy regimen
SOX/CapeOX	142	50.53%
FOLFOX	49	17.44%
DCF/DOF	30	10.68%
Capecitabine/S-1	22	7.83%
Others	38	13.52%
Best response
Complete remission	0	—
Partial response	37	13.17%
Stable disease	205	72.95%
Progression of disease	39	13.88%
Objective response rate	37	13.17%
Disease control rate	242	86.12%
Tumor biomarkers
CEA >5 ng/mL	121	43.06%
CA72-4 >6 U/mL	158	56.23%
CA19-9 >37 U/mL	106	37.72%
Hemoglobin (g/L)
<115	105	37.37%
≥115	176	62.63%
Albumin (g/L)
<35	52	18.51%
≥35	229	81.49%
Prealbumin (mg/L)
<160	83	29.54%
≥160	198	70.46%
Globulin (g/L)
≤35	259	92.17%
>35	22	7.83%
PGR
<7.21	139	49.47%
≥7.21	142	50.53%
AGR
<1.46	128	45.55%
≥1.46	153	54.45%

ECOG: Eastern Cooperative Oncology Group; TNM: tumor-node-metastasis; SOX: oxaliplatin + S1; CapeOX: oxaliplatin + capecitabine; FOLFOX: oxaliplatin + leucovorin + 5-fluorouracil; DCF: docetaxel + cisplatin + 5-fluorouracil; DOF: docetaxel + oxaliplatin + 5-fluorouracil; CEA: carcinoembryonic antigen; CA72-4: carbonhydrate antigen 72-4; CA 19-9: carbonhydrate antigen 19-9; PGR: prealbumin-to-globulin ratio; AGR: albumin-to-globulin ratio.